We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
Read MoreHide Full Article
Dr. Reddy's Laboratories Limited (RDY - Free Report) reported first-quarter fiscal 2022 earnings of 46 cents per American Depositary Share, compared with 47 cents in the year-ago quarter.
However, revenues grew 11% year over year to $662 million.
So far this year, shares of the company have rallied 1.8% against the industry’s decrease of 5.1%.
Image Source: Zacks Investment Research
Quarter in Detail
Dr. Reddy’s reports revenues under three segments — Global Generics; Pharmaceutical Services & Active Ingredients (“PSAI”); and Proprietary Products and Others.
Global Generics revenues were INR 41.1 billion, up 17% year over year, in the fiscal first quarter. Growth was led by branded markets (India and emerging markets) and Europe.
The company launched six products in North America, including Sapropterin Dihydrochloride Powder, Albendazole Tablets, Ertapenem Injection and Icosapent Ethyl Capsules in the United States, and two products in Canada.
PSAI revenues were INR 7.5 billion, down 12% from the year-ago quarter.
Revenues in the Proprietary Products segment came in at INR 541 million, down 1% year over year.
Research and development expenses surged 14% year over year to $61 million. The company is undertaking the development of products pertaining to COVID-19-related drugs.
Selling, general and administrative expenses were $202 million, up 18% year over year due to incremental costs post integration of the acquired divisions from Wockhardt and increased marketing expenses.
As of Jun 30, cumulatively, 93 generic filings were pending approval from the FDA (90 abbreviated New Drug Applications [ANDAs] and three new drug applications). Of these 93 ANDAs, 47 are Para IVs and 24 have first-to-file status.
Our Take
In first-quarter fiscal 2022, Dr. Reddy’s top line registered year-over-year growth while the bottom line declined slightly on a year-over-year basis.
The company continues to face price erosion, especially in the North America generics market, which is adversely impacting sales.
Dr. Reddys Laboratories Ltd Price, Consensus and EPS Surprise
Repligen’s earnings estimates have been revised 2.3% and 1.6% upward for 2021 and 2022, respectively, over the past 60 days. The stock has rallied 7.5% year to date.
Corcept’s earnings estimates have been revised 2.5% upward for 2021 and 3.1% upward for 2022 over the past 60 days.
Nabriva Therapeutics’ loss per share estimates have narrowed 10.1% for 2021 and 24.1% for 2022 over the past 60 days.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
Dr. Reddy's Laboratories Limited (RDY - Free Report) reported first-quarter fiscal 2022 earnings of 46 cents per American Depositary Share, compared with 47 cents in the year-ago quarter.
However, revenues grew 11% year over year to $662 million.
So far this year, shares of the company have rallied 1.8% against the industry’s decrease of 5.1%.
Image Source: Zacks Investment Research
Quarter in Detail
Dr. Reddy’s reports revenues under three segments — Global Generics; Pharmaceutical Services & Active Ingredients (“PSAI”); and Proprietary Products and Others.
Global Generics revenues were INR 41.1 billion, up 17% year over year, in the fiscal first quarter. Growth was led by branded markets (India and emerging markets) and Europe.
The company launched six products in North America, including Sapropterin Dihydrochloride Powder, Albendazole Tablets, Ertapenem Injection and Icosapent Ethyl Capsules in the United States, and two products in Canada.
PSAI revenues were INR 7.5 billion, down 12% from the year-ago quarter.
Revenues in the Proprietary Products segment came in at INR 541 million, down 1% year over year.
Research and development expenses surged 14% year over year to $61 million. The company is undertaking the development of products pertaining to COVID-19-related drugs.
Selling, general and administrative expenses were $202 million, up 18% year over year due to incremental costs post integration of the acquired divisions from Wockhardt and increased marketing expenses.
As of Jun 30, cumulatively, 93 generic filings were pending approval from the FDA (90 abbreviated New Drug Applications [ANDAs] and three new drug applications). Of these 93 ANDAs, 47 are Para IVs and 24 have first-to-file status.
Our Take
In first-quarter fiscal 2022, Dr. Reddy’s top line registered year-over-year growth while the bottom line declined slightly on a year-over-year basis.
The company continues to face price erosion, especially in the North America generics market, which is adversely impacting sales.
Dr. Reddys Laboratories Ltd Price, Consensus and EPS Surprise
Dr. Reddys Laboratories Ltd price-consensus-eps-surprise-chart | Dr. Reddys Laboratories Ltd Quote
Zacks Rank & Stocks to Consider
Dr. Reddy’s currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Repligen Corporation (RGEN - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and Nabriva Therapeutics plc , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’s earnings estimates have been revised 2.3% and 1.6% upward for 2021 and 2022, respectively, over the past 60 days. The stock has rallied 7.5% year to date.
Corcept’s earnings estimates have been revised 2.5% upward for 2021 and 3.1% upward for 2022 over the past 60 days.
Nabriva Therapeutics’ loss per share estimates have narrowed 10.1% for 2021 and 24.1% for 2022 over the past 60 days.